Correlation Between Inhibrx and China Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and China Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and China Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and China Pharma Holdings, you can compare the effects of market volatilities on Inhibrx and China Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of China Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and China Pharma.

Diversification Opportunities for Inhibrx and China Pharma

0.65
  Correlation Coefficient

Poor diversification

The 3 months correlation between Inhibrx and China is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and China Pharma Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on China Pharma Holdings and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with China Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of China Pharma Holdings has no effect on the direction of Inhibrx i.e., Inhibrx and China Pharma go up and down completely randomly.

Pair Corralation between Inhibrx and China Pharma

Given the investment horizon of 90 days Inhibrx is expected to generate 0.76 times more return on investment than China Pharma. However, Inhibrx is 1.31 times less risky than China Pharma. It trades about 0.0 of its potential returns per unit of risk. China Pharma Holdings is currently generating about -0.05 per unit of risk. If you would invest  2,543  in Inhibrx on October 3, 2024 and sell it today you would lose (1,003) from holding Inhibrx or give up 39.44% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Inhibrx  vs.  China Pharma Holdings

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Inhibrx are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
China Pharma Holdings 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days China Pharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong technical indicators, China Pharma is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

Inhibrx and China Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and China Pharma

The main advantage of trading using opposite Inhibrx and China Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, China Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Pharma will offset losses from the drop in China Pharma's long position.
The idea behind Inhibrx and China Pharma Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

CEOs Directory
Screen CEOs from public companies around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated